文献速递治疗药物监测与药物基因组学特殊人群用药

儿童炎症性肠病中抗TNF药物谷浓度药物遗传学研究

Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease.
PubMed 文献 · Br J Clin Pharmacol · 2020-07-01

AIMS: Identifying DNA variants associated with trough serum anti-tumour necrosis factor (TNF) levels could predict response to treatment in inflammatory bowel disease (IBD). To date, no specific studies have been performed in children.…

要点

  • TLR4 rs5030728和LY96 rs11465996与英夫利西单抗亚治疗浓度相关。
  • TLR2 rs1816702与阿达木单抗超治疗浓度相关,TNFRSF1B rs3397与亚治疗浓度相关。
  • TLR2 rs1816702是儿童IBD抗TNF方案个体化最有前景的标志物。

核心结论

  • 治疗前对相关DNA变异进行基因分型可能有助于为儿童患者选择最佳抗TNF药物。
  • SNP rs1816702是儿童IBD中定制抗TNF方案最有前景的标志物。
  • 首次发现DNA变异与抗TNF药物血清谷浓度相关。

研究设计与样本

  • 研究纳入来自17家医院的154例年龄小于18岁、诊断为IBD并正在接受英夫利西单抗或阿达木单抗治疗的儿童。
  • 采用酶联免疫吸附试验(ELISA)测定抗TNF药物血清谷浓度。
  • 采用Fisher精确检验、学生t检验和逻辑回归分析DNA多态性与抗TNF药物治疗窗或绝对值之间的关联。

主要发现

  • rs5030728(TLR4)和rs11465996(LY96)与英夫利西单抗亚治疗浓度相关(P < .05)。
  • rs1816702(TLR2)与阿达木单抗超治疗浓度相关,rs3397(TNFRSF1B)与阿达木单抗亚治疗浓度相关(P < .05)。
  • rs1816702(TLR2)和rs2569190(CD14)与阿达木单抗谷浓度绝对值相关,rs2569190(CD14)与阿达木单抗和英夫利西单抗谷浓度绝对值相关(P < .05)。

临床怎么用

  • 对于儿童IBD患者,在开始抗TNF治疗前可考虑对TLR2 rs1816702等位点进行基因分型,以辅助选择英夫利西单抗或阿达木单抗。
  • 根据基因分型结果结合治疗药物监测,可能有助于优化抗TNF药物的个体化治疗方案。

局限性

  • 研究仅纳入儿童患者,结论外推至成人需谨慎。
  • 样本量有限(154例),需更大规模研究验证。
  • 未报告基因分型对临床结局(如缓解率)的预测价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Identifying DNA variants associated with trough serum anti-tumour necrosis factor (TNF) levels could predict response to treatment in inflammatory bowel disease (IBD). To date, no specific studies have been performed in children. The aim of this study was to identify genetic variants associated with trough serum anti-TNF levels and whether these variants are differential markers for infliximab and adalimumab. METHODS: We included 154 children (age < 18 years) from 17 hospitals who had been diagnosed with IBD and actively treated with infliximab or adalimumab. Twenty-one polymorphisms were genotyped using real-time PCR. Trough serum anti-TNF levels were measured using enzyme-linked immunosorbent assay (ELISA). The association between DNA polymorphisms and the therapeutic range or the absolute values of anti-TNF drugs was analysed by Fisher exact test, student's t-test and logistic regression. RESULTS: The variants rs5030728 (TLR4) and rs11465996 (LY96) were associated with subtherapeutic infliximab levels. rs1816702 (TLR2) was associated with supratherapeutic levels and rs3397 (TNFRSF1B) with subtherapeutic levels of adalimumab (P < .05). In addition, rs1816702 (TLR2) and rs2569190 (CD14) were associated with absolute values of trough serum adalimumab, and rs2569190 (CD14) was associated with absolute values of trough serum adalimumab and infliximab (P < .05). CONCLUSION: Genotyping of these DNA variants before starting treatment may help to select the best anti-TNF drug in paediatric patients. The SNP rs1816702 is the most promising marker for tailoring the anti-TNF regimen in children with IBD. For the first time, DNA variants are associated with trough serum anti-TNF levels.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Salvador-Martín S, Pujol-Muncunill G, Bossacoma F, et al. Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease. Br J Clin Pharmacol. 2020. PMID: 32478906. doi:10.1111/bcp.14400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。